 FLORHAM PARK, N.J., May 24, 2021 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB, a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that they will host a company conference call on June 8, 2021 at 8:00 am ET, following the oral presentation of preliminary data of PDS0101 at the 2021 American Society of Clinical Oncology ASCO Annual Meeting. A press release summarizing the abstract data was issued on May 20. 